AI-assisted, human-published
06/02/2025 /Funding Events
SpyGlass Pharma Secures $75M to Advance Drug Delivery Platform
SpyGlass Pharma, a privately held ophthalmic biotechnology company, secures $75 million in Series D funding to further develop its Drug Delivery Platform for long-term treatment of glaucoma and other chronic ophthalmic diseases.
AI-assisted, human-published
Latest headlines
-
-
-
Stay connected!
If you have a serious, bonafide inquiry into the VentureCapital.com or PrivateEquity.com domain names, please contact us here
©2023 VentureCapital.com